Connect with us

Private Companies

Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target

Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock.  Awakn is a publicly traded company which trades on…

Published

on

Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock.  Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of AWKNF.  Let’s take a look at the stock’s upgrade and long-term potential in the context of psychedelics investing.

Awakn’s Upgrade Explained 

Stifel analyst Andrew Partheniou is predicting a bullish future for Awakn Life Sciences.  The stock market analyst has initiated coverage of the psychedelics stock, grading it as a Speculative Buy.  Partheniou also set an $8 price target for the stock.  

Awakn, based in Toronto, Canada was founded in 2020.  The company employs 18 people.  Awakn’s umbrella includes the subsidiaries of Mandala Therapy Limited and Axonklinikken AS.  Awakn’s stock is currently trading at $1.26.  The stock was trading at $2.44 on January 11.  Let’s shift gears to explain why analysts are becoming bullish on the stock.

The psychedelics industry is gradually making progress toward a mainstream tipping point.  Fast forward ...

Full story available on Benzinga.com

Read More

Trending